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Abstract
Background: Some degree of cognitive decline after surgery occurs in as many as one quarter of elderly surgical
patients, and this decline is associated with increased morbidity and mortality. Cognition may be affected
across a range of domains, including memory, psychomotor skills, and executive function. Whilst the exact
mechanisms of cognitive change after surgery are not precisely known, oxidative stress and subsequent
neuroinflammation have been implicated. N-acetylcysteine (NAC) acts via multiple interrelated mechanisms
to influence oxidative homeostasis, neuronal transmission, and inflammation. NAC has been shown to reduce
oxidative stress and inflammation in both human and animal models. There is clinical evidence to suggest
that NAC may be beneficial in preventing the cognitive decline associated with both acute physiological
insults and dementia-related disorders. To date, no trials have examined perioperative NAC as a potential
moderator of postoperative cognitive changes in the noncardiac surgery setting.
Methods and design: This is a single-centre, randomised, double-blind, placebo-controlled clinical trial, with a
between-group, repeated-measures, longitudinal design. The study will recruit 370 noncardiac surgical patients
at the University Hospital Geelong, aged 60 years or older. Participants are randomly assigned to receive
either NAC or placebo (1:1 ratio), and groups are stratified by age and surgery type. Participants undergo a
series of neuropsychological tests prior to surgery, 7 days, 3 months, and 12 months post surgery. It is
hypothesised that the perioperative administration of NAC will reduce the degree of postoperative cognitive
changes at early and long-term follow-up, as measured by changes on individual measures of the neurocognitive
battery, when compared with placebo. Serum samples are taken on the day of surgery and on day 2 post surgery
to quantitate any changes in levels of biomarkers of inflammation and oxidative stress.
Discussion: The PANACEA trial aims to examine the potential efficacy of perioperative NAC to reduce the severity of
postoperative cognitive dysfunction in an elderly, noncardiac surgery population. This is an entirely novel approach to
the prevention of postoperative cognitive dysfunction and will have high impact and translatable outcomes if NAC is
found to be beneficial.
Trial registration: The PANACEA trial has been registered with the Therapeutic Goods Administration, and the
Australian New Zealand Clinical Trials Registry: ACTRN12614000411640; registered on 15 April 2014.
Keywords: Anaesthesia and cognitive deficit, Cognitive dysfunction, Anaesthetics, Surgery, Oxidative stress,
N-acetylcysteine, Antioxidant, Surgical stress response, Delirium, Dementia
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Background
Cognitive decline after surgery is common amongst elderly
surgical patients [1–3]. Postoperative cognitive dysfunction
(POCD) refers specifically to dysfunction in postoperative
cognitive performance relative to presurgical performance;
however, the exact threshold delineating when cognitive
decline can be classified as POCD varies considerably
within the literature [4]. One of the most robust studies
places the early postoperative incidence rate of POCD at
approximately 25 % of major surgery patients, aged over
60 years [1, 3, 4], and research suggests that patients aged
at least 60 years are at significantly greater risk compared
to younger patients [37]. Generally, cognitive decline after
surgery manifests as subtle dysfunction across a number of
cognitive domains, such as memory, attention, and psycho-
motor function. It may persist in some patients for months
or years and herald the onset of a dementia process, to the
significant detriment of quality of life [5–8]. Given the lack
of consensus regarding the exact demarcation of POCD, it
is useful to refer instead to an absolute difference in cogni-
tive function after surgery controlling for baseline values,
regardless of whether or not such a change in function
meets the specifications for POCD.
At present, there are neither pharmacological inter-
ventions nor preventative agents for POCD. The role of
oxidative stress and neuroinflammation as a result of a
surgical stress response is well-characterised, and now
provides a potentially modifiable target for therapeutic
intervention [9–13]. Developing evidence suggests that
there is a relationship between surgery and anaesthesia
and the production of inflammatory signals and reactive
oxygen species in the periphery and the brain which are
associated with cognitive dysfunction [14–19].
Why N-acetylcysteine?
N-acetylcysteine (NAC) provides the rate-limiting mol-
ecule, cysteine, for glutathione production. Glutathione
is the major antioxidant species in the brain, enhancing
the brain’s capacity to respond to oxidative stress condi-
tions which are associated with cognitive deficits [20, 21].
NAC also mitigates the negative effects of inflammation
on cognition, suppressing overactivation of the brain’s in-
flammatory cells and dysregulation of the key neuro-
transmitter glutamate [22–24]. Commonly used in cases
of acetaminophen overdose to protect against liver dam-
age [58], in recent decades NAC has been studied as an
intervention agent for a wide variety of neuropsychiatric
disorders including cocaine dependence, trichotillomania,
schizophrenia, depression, and bipolar disorder [54, 59].
Importantly, NAC is also effective in reducing cognitive
deficits in preclinical models of Alzheimer’s disease via
modulation of inflammation and oxidative stress [25–28].
NAC has been found to be beneficial in the clinical set-
ting for a variety of psychiatric, neurological, and medical
conditions with cognitive sequelae, including late-stage
Alzheimer’s disease [29–32]. However, the administration
of NAC in these settings typically forms a part of a supple-
ment cocktail containing other substances with putative
cognitive modulation [29–32] and so an investigation of
NAC in addition to regular treatment is necessary. Fur-
ther, studies examining the efficacy of NAC as a cognitive
modulator in a clinical population are typically heteroge-
neous concerning dose strength and regimen [59], thus
making consensus difficult. NAC has demonstrated effi-
cacy in reducing the elevations of markers of inflamma-
tion and oxidative stress seen after major surgery; markers
which are now thought to be predictive of risk of cognitive
sequelae [33–35]. No study to date has directly examined
human cognition after perioperative administration of
NAC. Hence, we propose NAC may protect against post-
surgical cognitive decline in the at-risk population.
Aims
Primary
 To investigate the effectiveness of NAC in reducing
the severity of cognitive decline following major
elective noncardiac surgery
Secondary
 To investigate the effectiveness of NAC in reducing
biomarkers of inflammation and oxidative stress in
the perioperative setting
 To examine correlations between changes in
cognition and biomarkers
 To identify potential predictors of cognitive change
following surgery
Hypotheses
Primary
 That administration of NAC in the perioperative
setting is superior to placebo for reducing the
severity of early POCD, as measured by changes in
performance on the psychomotor-attention composite
of the CogState Brief Battery (CBB)
Secondary
 That administration of NAC in the perioperative
setting is superior to placebo for reducing the severity
of enduring cognitive change in the late postoperative
period, as measured by changes in performance on
the psychomotor-attention composite of the CBB
3 months post surgery, and 1 year post surgery
 That administration of NAC in the perioperative
setting is superior to placebo for reducing the
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severity of cognitive change in the early
postoperative period, as measured by changes on the
Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS), the Controlled
Oral Word Association Test (COWAT), and Trail
Making Tests A and B (TMT) 7 days post surgery
 That administration of NAC in the perioperative
setting is superior to placebo for reducing the
severity of cognitive change in the late postoperative
period, as measured by changes on the RBANS,
COWAT, and TMT at 3 months post surgery, and
1 year post surgery
 That administration of NAC in the perioperative
setting is superior to placebo for reducing serum
levels of biomarkers of inflammation and oxidative
stress in the postoperative phase
 That there is an inverse correlation between
performance on the neuropsychological battery and
serum biomarkers of oxidative stress, at baseline, in
the postoperative period and at follow-up
Methods and design
A single-centre, randomised, double-blind, placebo-
controlled clinical trial. A total of 370 participants
are randomised into either a placebo or treatment
(NAC) group in a 1:1 ratio.
Trial procedures
Participants undergo an initial recruitment and screening
interview, a baseline assessment of cognition, mood, and
quality of life prior to surgery, and follow-up visits at post-
surgery day 2, day 7, 3 months, and 12 months. Serum
sampling for biomarker assessment occurs immediately
prior to surgery, and then again on postsurgery day 2 to
correlate with peak oxidative stress levels (Fig. 1, Table 1).
The SPIRIT checklist is provided as an Additional file 1.
Setting and participants
The study is being conducted at the University Hospital
Geelong, a public teaching hospital that caters for the
majority of surgical subspecialties other than neurosur-
gery, organ transplantation, and cosmetic plastic surgery.
Patients undergoing major noncardiac surgical procedures
of vascular; ear, nose, and throat; plastic; gynaecological;
orthopaedic; urological; ophthalmological; and general
surgery are invited to participate. Based upon data from
the 2014 calendar year, there are over 1000 potentially eli-
gible patients annually. Potential participants are identified
and approached during presurgical outpatient clinics by
experienced research nurses. Perspective participants are
provided with an Information and Consent Form that
must be signed and witnessed by a member of the re-
search team before enrolment. Participant visits will take
place at University Hospital or at the home of the partici-
pant where applicable.
Regulatory approval
Barwon Health Human Research Ethics Committee and
Deakin University Human Research Ethics Committee
have provided ethics approval. Approval was required,
and granted by, the Therapeutic Goods Administration
(TGA) under the Clinical Trials Notification Scheme to
conduct the study.
Inclusion criteria
Patients aged 60 years or older who are undergoing
major elective noncardiac surgery, defined as surgery
expected to last at least 1 h in duration and requiring
Fig. 1 Trial flow chart. A graphical flow chart of the trial process, from recruitment and randomisation to the final data collection at 12 months
Skvarc et al. Trials  (2016) 17:395 Page 3 of 11
admission to hospital for at least two nights, are eligible
for recruitment. This is in accordance with findings from
the seminal International Study of POCD, where increased
length of surgery was significantly associated with in-
creased risk of POCD after approximately 1 h [1, 2].
Exclusion criteria
Participants are ineligible to take part if they:
 Have known contraindications to NAC, including
allergies and concomitant nitrate therapy
 Are unable to comply with the requirements of
informed consent or the study protocol
 Are already taking NAC
 Are undergoing carotid endarterectomy, due to the
high incidence of perioperative cerebrovascular
accidents after this procedure [36]
 Are undergoing surgery for trauma
 Lack the capacity to consent to their own surgery
Randomisation, allocation, and concealment
Once consent is confirmed, participants are randomised
to a treatment group. Randomisation is stratified by sur-
gery type (orthopaedic or nonorthopaedic) and age (less
than 80 years or 80 years or older) to provide four strata
for the study. The allocation code was produced by an
independent researcher prior to the commencement of
recruitment and was generated by a computer-generated
list, using permuted block randomisation with variable
block sizes. The allocation code is concealed to all trial
personnel, with the exception of the dispensing pharma-
cist. The pharmacist allocates the participant number,
based on the relevant stratum and holds the code if
unblinding is required, but is not involved in data collec-
tion. All other relevant persons, including investigators,
research assistants, research nurses, and participants are
blind to the treatment allocation until the end of the
data analysis.
To aid treatment concealment, all trial materials appear
identical. Further, the placebos have been dusted with a
nontherapeutic amount of NAC to assist with matching
odours (given that NAC has a strong odour). The placebos
and NAC capsules are identical in size, taste, and appear-
ance. All trial medication is provided in identical bottles.
Any unused medication is returned to the pharmacy for
auditing.
Stratification by age enhances parity between groups
in terms of its effects upon cognition, in accordance with
established risk factors [5, 37]. Despite the relative safety
and success of orthopaedic operations compared with non-
orthopaedic operations, the risk of cognitive dysfunction is
still significant [3]. Accordingly, orthopaedic patients repre-
sent an opportunity to examine potential cognitive change
that is less likely attributable to other factors. Additionally,
stratification by orthopaedic and nonorthopaedic counter-
acts the wide variability of reported POCD in the literature
[38]. Meta-analyses suggest small cognitive improvements
from pooled data yet individual studies note an incidence
of POCD as high as 45 % [38]. It is widely held that this
variability is due mostly to discrepancies in diagnostic cri-
teria [39] but the concern remains that a significant subset
of individuals within the orthopaedic cohort do experience
cognitive improvement. The literature to date has not pro-
vided the means to identify them prospectively, but it has
Table 1 Timeline of instruments
Instruments Recruitment Prior to surgery Day of surgery POD1 POD2 POD3 POD7–14 3–4 months 12–13 months
MMSEa X
CBBb X X X X
RBANSb X X X X
COWATb X X X X
TMTb X X X X
CAMa X X
HADSb X X X X
WHOQOL-BREFb X X X
NRS11a X X X
Modified Brief Pain Inventoryb X
Neuropathic Pain Questionnaireb X
Research blood sample – biomarkersa X X
A table with assessment and data collection types listed as rows, and data collection points in columns. The corresponding collection point for each assessment is
marked with an ‘X’”. This conforms with the SPIRIT guidelines (Additional file 1)
CAM Confusion Assessment Method, CBB CogState Brief Battery, COWAT Controlled Oral Word Association Test, HADS Hospital Anxiety and Depression Scale,
MMSEMini Mental State Exam, NRS11 Numerical Rating Scale for Pain, POD postoperative day, RBANS Repeatable Battery for the Assessment of Neuropsychological
Status, TMT Trail Making Tests A and B, WHOQOL-BREF World Health Organisation Quality of Life scale
aTo be performed by trained research staff
bTo be performed by research staff trained in the neuropsychological assessment
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been suggested that a low cognitive baseline secondary to
chronic inflammation, pain, opioid consumption, and re-
stricted mobility, coupled with the potential for surgical
remedy, is a potent confounder of postsurgical cognition
[40]. This complex and not yet fully characterised surgical
profile suggests that the broad classification of surgeries
into orthopaedic and nonorthopaedic may help to minim-
ise any confounding in the collected data, with negligible
loss of power with respect to a nonstratified design.
Dose and treatment regimen
Administration of NAC in a wide variety of medical set-
tings has been shown to be safe [41, 42]. Whilst there is
variation within the literature regarding dose and timing
of NAC, recent reviews have suggested NAC adminis-
tered per os at doses of 2400 mg/day to be efficacious in
delivering demonstrable biomarker change with a negli-
gible adverse effect profile [43, 44]. Kuyumcu et al. [33]
showed improved oxidative status in abdominal surgery
patients with a total dose of 2400 mg of NAC adminis-
tered intravenously over 2 days prior to surgery. Dose
regimens well in excess of 2400 mg/day have been safely
explored with some regularity, but are likely to be bur-
densome during oral administration, a route which of-
fers greater safety [62] and ease of administration than
intravenous infusion. Bearing in mind the previously estab-
lished effective doses, the expected duration of the surgical
stress response [42], the oral bioavailability of NAC and
the relative ease, safety and cost effectiveness of oral ad-
ministration, we have chosen a regimen of 1200 mg NAC
administered per os twice daily, consisting of two 600-mg
capsules in the morning and again in the evening, starting
on the day of surgery and continuing for 4 days to a total
cumulative dose of 9600 mg. Administration takes place
during the patients’ regular morning and evening drug
rounds, facilitated by the ward staff and recorded from the
patient chart by the research nurses. Placebo is adminis-
tered in an identical fashion. Medication is dispensed by
the pharmacy and administration coordinated by the re-
search nurses, and recorded in the trial records for each
participant. Unused medication is returned to the phar-
macy for disposal. Episodes of nausea and vomiting are
recorded by research staff.
Assessments and information
Demographic data and details of participants’ medical
history are recorded to explore potential risk factors and
confounders, gathered from participant interview, chart
review, and examination of medical history. The following
variables are specifically sought to identify potential predic-
tors of outcome: age, gender, participants who identify as
having Aboriginal and Torres Strait Islander descent, edu-
cational attainment, chronic inflammatory diseases (such
as rheumatoid arthritis), osteoarthritis and inflammatory
bowel disease, medications with anti-inflammatory proper-
ties (including statins, NSAIDs and steroids), preexisting
psychiatric conditions and/or medication, and vascular risk
factors including diabetes, total cholesterol, smoking status,
hypertension, atrial fibrillation, heart disease – ischaemic/
cardiac failure, and previous transient ischaemic attack/
stroke.
Cognitive function measures
Cognitive function is assessed prior to surgery, 7 days post
surgery, 3 months post surgery, and again 12 months post
surgery. Cognitive dysfunction at approximately 1 week
post surgery has been shown to be a significant predictor
of further cognitive change in elderly postsurgical patients,
and so comparisons of cognition at postoperative day
(POD) 7 with preoperative baseline is considered the pri-
mary outcome [37]. A number of cognitive domains are
measured using a selection of validated neuropsycho-
logical tests. All assessments are reliable and validated for
the use in detecting cognitive change [45–51, 61, 62]. All
assessments, with the exception of the CBB, are recorded
in specially created Case Report Forms, and stored se-
curely after the transcription of data into the secure
computer database (Research Electronic Data Capture,
REDCap). The CBB automatically uploads data into a
secure database, and does not require paper records.
All assessments are performed by trained research staff,
supervised for compliance and quality by the senior cli-
nicians. Psychomotor, attention, learning, and working
memory domains are assessed with the computerised
CBB. The CBB consists of four tasks: detection, identifica-
tion, one-card learning, and one-card back. In the detec-
tion task, the participant is asked to press a button as
soon as a displayed card is turned over. The psychomotor-
attention composite is made up of the detection and iden-
tification tasks on the CBB and represents the reaction
time of the participant, where higher scores indicate lower
reaction speed and can be used to suggest the presence of
impairment. The CBB has shown efficacy in detecting
cognitive change in healthy participants over 12 months
[60], and in clinical samples. [45]. Immediate memory,
visuospatial, and delayed memory domains are assessed
with the Repeatable Battery for the Assessment of Neuro-
psychological Status (RBANS) [46]. The RBANS consists
of 12 subtests measuring immediate and delayed verbal
and visuospatial memory, and is commonly used for the
detection of cognitive change [46]. Alternate forms are
used at each assessment.
Verbal fluency and executive function is assessed with
the Controlled Oral Word Association Test (COWAT).
Over three attempts, participants are given 1 minute to
list as many words beginning with a specified letter.
Errors and perseverations are recorded [47].
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Visuospatial and executive function is assessed with the
Trail Making Tests A and B (TMT). Participants are asked
to connect a series of numbered scattered dots in sequen-
tial order. Only numbered dots are used in Test A; alter-
nating numbers and letters are used in Test B [48].
Delirium assessment
Postoperative delirium typically manifests between 24
and 72 h post surgery, and may last up to several days
[61]. Delirium is assessed on POD 2 and POD 7 using
the short form of the Confusion Assessment Method
instrument (CAM) [49].
Mood disorder measurement
‘Depression and Anxiety’ is assessed prior to surgery, 7 days
post surgery, 3 months post surgery, and 12 months post
surgery using the HADS questionnaire. The HADS is a
brief self-report Likert scale where participants report how
well a depressive or anxious symptoms describes them in
the past 7 days (e.g. ‘I felt tense or “wound up”’ [50]).
Quality of life measurement
Quality of life is assessed prior to the operation, at 3 months
post surgery, and again at 12 months post surgery using
the World Health Organisation Quality of Life – BREF
questionnaire (WHOQOL-BREF) [51].
Blood levels of inflammation and oxidative stress
Serum samples are collected during placement of an intra-
venous line during surgery (baseline), and again in con-
junction with routine postoperative bloods on postsurgery
day 2. This is timed to capture the approximate time of
peak postoperative inflammatory markers of approximately
24–72 h post surgery [52]. Blood samples (30 ml) are taken
by research staff and spun in equal portions into separate
plasma, serum, and whole blood aliquots. These are then
stored onsite at −80 °C in preparation for analysis by re-
search staff at the end of data collection.
Whilst surgery and anaesthesia are associated with a
systemic inflammatory response, patients who develop
POCD tend to show higher levels of inflammatory markers,
including interleukin-(IL)1β [52, 53], relative to those with
intact cognition. Similarly, markers of oxidative stress, pre-
viously correlated to neuroinflammation, may be upregu-
lated in POCD [52]. Circulating inflammatory factors are
thought to potentiate neuroinflammation through stimula-
tion of microglia, which produce both pro-inflammatory
cytokines and potent reactive oxygen species and are in-
strumental in neuronal dysfunction [45]. Thus, measure-
ment of peripheral inflammation and oxidative damage
are reflective of not only systemic inflammation in the
postoperative context but also central neuroinflammatory
processes. We intend to examine a panel of related bio-
logical correlates, focusing on inflammatory cytokines, the
primary CNS antioxidant species and markers of oxidative
damage to lipid, DNA, and protein. Unspecified consent
has been requested to allow for the exploration of relevant
biological markers should they be identified during the
course of the trial. Changes in peripheral markers will be
correlated to clinical improvements.
Perioperative assessment of pain
A numerical rating of perioperative pain experienced by
the participants is recorded at baseline, POD 2 and POD
7 using the Numerical Rating Scale-11. Additionally, the
Modified Brief Pain Inventory is conducted at 3 months,
and the Neuropathic Pain Questionnaire is conducted at
12 months.
Outcome variables
Primary outcome variable:
 A between-group comparison of cognitive performance
in the early postoperative period (day 7), as measured
using the psychomotor-attention composite score of
the CogState Brief Battery (CBB)
Secondary outcomes:
 Between-group comparison of cognitive
performance in the early and late postoperative
period, as measured using the extended
neuropsychological battery, at day 7, 3 months, and
1 year post surgery. Comparisons at each time point
will be made to scores obtained at presurgical
baseline
 Between-group comparison of mood disorder, as
measured using the Hospital Anxiety and
Depression Scale (HADS), at day 7, 3 months, and
1 year post surgery. Comparisons at each time point
will be made to raw scores obtained at presurgical
baseline
 Between-group comparison of quality of life, as
measured using the World Health Organisation
Quality of Life – BREF (WHOQOL-BREF) scale, at
3 months, and 1 year post surgery. Comparisons at
each time point will be made to raw scores obtained
at presurgical baseline
 Between-group comparison of delirium, as measured
using the Confusion Assessment Method (CAM), on
postsurgery days 2 and 7. Incidents of delirium are
recorded dichotomously
 Between-group comparison of postoperative pain,
as measured using the Numerical Rating Scale
(NRS) on postsurgery days 2 and 7; the Modified
Brief Pain Inventory at 3 months, and the
Neuropathic Pain Questionnaire at 12 months
post surgery
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 Between-group comparison of levels of serum
neuroinflammation and oxidative stress, including
but not restricted to, tumour necrosis factor
(TNF)α, IL-1β IL-6, S100β, malondialdehyde, and
reduced and oxidised glutathione on postsurgery
day 2
Withdrawal
Participation is entirely voluntary and consent may be
withdrawn at any stage. Withdrawal reasons are docu-
mented and recorded. Participants are not considered
to have withdrawn if they are lost to follow-up, and re-
search staff will attempt to reconnect with participants
for subsequent assessments. For example, a participant
who is unable to be contacted for the 3-month follow-
up is recorded as a missed session, but research staff
will attempt to contact the participant for the 12-month
follow-up. Participants are withdrawn from treatment
and/or assessment if they:
 Withdraw consent for participation
 Are unblinded for any purpose prior to the end of
the treatment period
 Are requested to withdraw by their treating medical
team due to interference with their appropriate
clinical management
 Require subsequent surgery or anaesthesia prior to
measurement of the primary outcome variable
Adverse events
Adverse events (AEs), serious adverse events (SAEs), and
suspected unexpected serious adverse reaction (SUSAR)
monitoring and reporting are conducted in strict accord-
ance with the processes established by both governing
ethics committees.
AEs are recorded from the time that informed consent
has been obtained until the end of the 12-month study
period. For each, the following parameters are described:
 The investigator’s assessment of the causal
relationship between the event and the
investigational treatment
 A description of the AE, including its nature, start
and stop date, action taken with regards to the
investigational treatment, intensity and outcome
 A statement if the AE fulfils the criteria for an SAE
or a SUSAR
Intensity is determined according to the following
categories:
 Mild: an AE which is easily tolerated by the
participant, causing minimal discomfort and not
interfering with everyday activities
 Moderate: an AE which is sufficiently discomforting
to interfere with everyday activities
 Severe: an AE which is incapacitating and prevents
everyday activities and/or requires therapeutic
intervention, i.e. use of a prescription drug or
hospitalisation
Follow-up of adverse events and SUSARs
AEs are followed up until either they are resolved, or
persist despite cessation of the trial medication and
its elimination from the body (given that the half-life
of NAC is roughly 6 h, this is estimated to take 2
days). AEs may be followed up for longer at the dis-
cretion of the investigators.
Reporting of serious adverse events and SUSARs
Reporting of SAEs to regulatory authorities is done
within the requisite 24-hour period by an investigator in
accordance with local regulations. A copy of the SAE
report is sent to the Barwon Health Human Research
and Ethics Committee, the sponsor and the principal
investigator. If unblinding is required, a report will also
be sent to the Therapeutic Goods Administration.
Mortality reporting
Regardless of causality or which randomisation arm the
participant is assigned to, all cases of mortality are re-
ported to the Data Safety Management Board and regu-
latory authorities.
Termination and safety
It is intended that the trial will run for the projected
duration of 4 years from recruitment of the first patient.
A DSMB has been established for this study and is
independent of the investigators. Investigators provide
intermittent reports to the DSMB with any informa-
tion relating to safety analyses, and monitor instances
of adverse. The DSMB provides recommendations re-
garding the continuation of the study.
Sample size determination
Due to variations in definitions and cut-off criteria, meas-
uring the effects of POCD, in the context of previous
literature, is extremely difficult. Additionally, there is no
literature available examining the use of the CBB for the
detection of POCD, despite being theoretically suited to
the task. However, literature that examines differences be-
tween healthy controls and mild cognitive impairment
(MCI) provides a close approximation of the quantifiable
effects of cognitive change after surgery. An examination
of the available research utilising the CBB provides an
estimated effect size of cognitive change in compari-
son to healthy controls, MCI, and Alzheimer’s disease
participants.
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The literature suggests a strong correlation between
the two tasks of the psychomotor-attention composite,
detection and identification, for simplicity’s sake assumed
to be in the region of r = 0.8 is expected (for example, see
the similarities present on scores from the research of
Hammers et al., 2012; [55] and Lim et al., 2012 [56]).
Further, the variances for pre and postsurgery will be stan-
dardised to 1. The variance of the composite is calculated
as the sum of pre and postsurgical variances plus twice
the correlation of the composite tasks; 2 + 2 (0.8) = 3.6.
Therefore, to estimate the effect of MCI (and by exten-
sion, cognitive change after surgery), we divide the com-
bined effect size for the psychomotor-attention composite
by the standard deviation of the effect size, that is the
square root of the variance of the composite. From Lim et
al., the effect of MCI size of the change in reaction speed
for the detection and identification tasks were −0.33 and
−0.63, respectively, giving a total reduction in reaction
speed effect size of −0.96. Therefore, the total effect of
MCI (and by extension, cognitive change after surgery)
upon the psychomotor-attention composite is equal to:
−0.96/√3.6 = −0.51. Given that NAC is unlikely to improve
cognition beyond baseline estimates, it is proposed that
NAC may instead ameliorate the severity of cognitive dys-
function compared with placebo. Given the limited avail-
able data, we have attempted to estimate an approximate
protective effect based on the use of NAC in analogous
conditions, such as traumatic brain injury [63]. Addition-
ally, it is unrealistic to assume complete prevention of
cognitive dysfunction. Therefore, a relative reduction in
severity of cognitive dysfunction of 50 % represents an
appropriate compromise to calculate the power. Given the
likelihood of significant correlation in pre and postsurgery
cognition scores, and in the absence of any identifiable
correlation size, it is prudent to include an estimation of
correlation patterns in the medium range (r = 0.50). A
protective effect of NAC of 50 % would then set the
expected effect of postoperative cognitive change as mod-
ulated by NAC at = −0.255. Assuming an alpha level of
0.05, power of 80 %, and a pre and postsurgical score
correlation of 0.5, a sample size of 370 participants will
have 80 % power to detect a minimum absolute effect
size of 0.255 using an analysis of covariance (ANCOVA)
model. This sample size includes approximately equal rep-
resentation across stratification by age and surgery type
for intervention.
Primary analysis
The primary study hypothesis states that the perioperative
administration of NAC is superior to placebo in reducing
the severity of postoperative dysfunction, as measured by
the CBB at POD 7, and compared with baseline. Analysis
of the primary outcome will be via ANCOVA, utilising
the baseline psychomotor-attention composite score as
a covariate. Assumptions of the ANCOVA will be ex-
amined through standard tests and residual plots, with
transformation of variables being considered if normality
of the residuals is not met. The psychomotor-attention
composite is made up of the detection and identification
tasks on the CBB and represents the reaction time of the
participant, where higher scores indicate lower reaction
speed and can be used to suggest the presence of impair-
ment. The composite score is calculated by standardising
each task score and adding them together. All analyses
will be performed as intent-to-treat, in order to best emu-
late practice settings.
Secondary analyses
Linear mixed-model ANCOVA will be conducted to model
the differences in cognitive changes between treatment
groups by fitting a linear curve to represent the relation-
ship between performance on tasks and time point. The
magnitude of the differences between treatment groups
will be expressed as Cohen’s d.
Between-group differences on the individual tasks of
the neuropsychological battery will be examined. Similar
to the primary analysis, an ANCOVA will be used to
examine the performance of participants on each of the
neuropsychological battery tasks. Included in the analyses
will be the individual CBB tasks, detection, identification,
one-card back, and one-card learning; RBANS tasks, the
COWAT, and Trail Making Tests A and B. Data will be
represented as a linear mixed-effects model, comparing
the performance of the NAC group compared to the
control group over time. The magnitude of difference
between treatment groups will be calculated as Cohen’s d.
Between-group differences on measures of delirium and
mood dysfunction will be analysed using a chi-square test
using the CAM and HADS measures. Participants will be
classified dichotomously as displaying symptoms of delir-
ium or mood dysfunction according to established cut-off
points; 11 points on either anxiety or depression for the
HADS, or fulfilment of delirium criteria according to the
CAM.
Between-group differences on measures of quality of life
will be analysed using an ANCOVA to examine changes
over the course of the trial, controlling for baseline values
as a covariate. Between-group differences will be exam-
ined for change across time from baseline scores to
3 months and 12 months. A linear mixed-effects model
will be used to represent the data comparing treatment
groups, with the magnitude between treatment groups
expressed as Cohen’s d.
Between-group differences in serum levels of biological
markers will be examined prior to surgery and at POD2 in
order to capture the surgical stress response. An ANCOVA
will be performed to examine the between-group differ-
ences over time, with baseline values acting as a covariate.
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Data will be graphed using a linear mixed-effects model,
with the magnitude of difference between treatments
groups expressed as Cohen’s d.
A bivariate correlation analysis exploring serum bio-
logical marker levels and cognitive function will be calcu-
lated for each of the battery tasks.
Exploratory analyses
Subgroup analyses will be undertaken to examine the
role of variables that may contribute to risk factors asso-
ciated with POCD, such as demographic information,
health and medical history, socioeconomic status, and
other data collected during the study. These subgroup
analyses can be examined using a multilevel modelling
approach. For example, by treating the presence of POCD
in a participant as an outcome level, it will be possible to
examine the relative contributions of each independent
variable to POCD (e.g. varying treatment effects for differ-
ing levels of demographics). This approach can also be ex-
panded to further examine other participant outcomes,
such as the presence of delirium, mood dysfunction,
or a significant change in quality of life. For explora-
tory analyses focussed upon proportionate data, such
as comparisons of dichotomous delirium or mood dys-
function outcomes, McNemars’ test can be used to exam-
ine within-groups differences across time points. The role
of perioperative pain upon POCD may also be explored as
a potential cognitive trajectory modulator.
Missing or incomplete data
All participants recruited into the study, regardless of
treatment group, are to have as much data as possible
recorded, as fully as possible in accordance with this
protocol. Missing data is monitored so as to avoid bias
by attrition or patterns of missing data. All cases of miss-
ing data, including instances of nonretention of partici-
pants or withdrawal of consent, are to be recorded by
research staff. Where data is missing, the frequency and
reasons for missing data are to be recorded. Missing data
is to be examined to see if there are patterns informative
to the study; for example, if certain variables are missed in
a systematic way by an identifiable pattern of participant.
In situations where data is missing, for example with
participants who are lost to the 12-month follow-up, the
data collected up to that point should still be used pro-
vided the participant has not withdrawn their consent or
requested that the information be removed. If missing
data is considered Missing at Random (MAR, i.e. with-
out a pattern), then multiple imputation methods should
be used to estimate missing values. The accepted mini-
mum number of imputations is five, to estimate the miss-
ing data from existing data. This can be achieved using
statistical software. If data appears to be missing in a way
that is not random (Missing Not At Random, MNAR),
then this data can be examined for potential biases or
patterns statistically, and missing values can then be
estimated using monotonistic methods.
Discussion
Our study is the first randomised controlled clinical trial
on the efficacy of perioperative NAC administration upon
cognition. Because the trial will aim to recruit 370 partici-
pants and primarily examine the efficacy and safety of
NAC, we consider this to be a phase 2 trial.
Australia’s population is ageing, and will continue to re-
quire greater numbers of surgical procedures. The com-
monness of cognitive dysfunction after surgery [1, 3, 4, 38],
and the significantly increased risk of expedited morbidity
and mortality [5–8], provide a strong community motiv-
ation to investigate potential interventions and it is hoped
that NAC may fulfil that need.
The PANACEA trial is not without limitations, particu-
larly the risk of attrition common in longitudinal studies.
The potential for increased risks of nausea and vomiting
may also result in participant withdrawal. Whilst all rea-
sonable attempts to reduce the influence of attrition bias
are employed, the possibility cannot be ruled out.
Trial status
The PANACEA trial commenced recruitment in March
2015. The study has been registered with the Thera-
peutic Goods Administration, and the Australian New
Zealand Clinical Trials Register (ANZCTR): ACTRN
12614000411640. The study is performed in accordance
with ethical and good clinical practice principles detailed
by the Declaration of Helsinki and International Confer-
ence on Harmonisation [57].
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